摘要 :
Background Longer-term symptoms (long COVID) may be present in seemingly recovered patients for several months and can be debilitating.AimTo investigate the prevalence and type of symptoms in those with a prior COVID-19 diagnosis....
展开
Background Longer-term symptoms (long COVID) may be present in seemingly recovered patients for several months and can be debilitating.AimTo investigate the prevalence and type of symptoms in those with a prior COVID-19 diagnosis.Methods This prospective, longitudinal observational study commenced in July 2020 investigating the longer-term health impacts of COVID-19. Participants were recruited via public health units and media publicity. Surveys were completed upon enrolment, and at 1, 3, 6 and 12 months. Outcome measures included incidence of activity limitations and symptoms against health and vaccination status, age and gender.Results Overall, 339 participants were recruited. At 3 months after COVID-19, 66.8% reported symptoms, and 44.8% were still experiencing symptoms at 12 months. Fatigue was most common at every point (between 53.1% and 33.1%). Pain symptoms increased in relative prevalence over time, whereas respiratory/pulmonary-type symptoms decreased substantially after 3 months. Females and younger people were more likely to experience symptoms in the early stages of long COVID (P < 0.01) and those with more comorbidities in the latter stages (P < 0.001). Vaccination showed a statistically significant protective effect against symptoms (P < 0.01-0.001).Conclusion Long-term COVID-19 symptoms exist among recovered patients up to 12 months after contracting the virus. Fatigue is a primary contributor, while chronic pain became more problematic after 6 months. Vaccination was a factor in preventing long-term symptoms and aiding faster recovery from symptoms. Further work exploring additional contributors to symptom prevalence would assist in developing appropriate follow-up care.
收起
摘要 :
Proper oral health care has an impact on the health of the entire body. The COVID-19 pandemic has affected the functioning of the healthcare sector, including dental services. The aim of this study was to analyse the behaviour of ...
展开
Proper oral health care has an impact on the health of the entire body. The COVID-19 pandemic has affected the functioning of the healthcare sector, including dental services. The aim of this study was to analyse the behaviour of patients with regard to their use of dental services during the pandemic. The data were obtained from paper registration forms taken from five dental offices in the city of Cracow between March 2019 and February 2021. During the analysed periods, interest among first-time patients in dental services decreased to 37% (during the month when interest in dental services was at its lowest) compared to the year preceding the COVID-19 pandemic. The number of cancelled visits increased by between 15% and 50% compared to the pre-pandemic period. During the pandemic, appointments made by existing patients increased by up to 84% compared to 2019. The decision by patients to postpone dental treatment not only has adverse effects on their oral and body health, but in turn results in higher health care costs. Given the potential for another pandemic, further long-term research is required to develop and implement special protocols to make the public aware of the safety of health care.
收起
摘要 :
The coronavirus disease 2019 (COVID-19) is a novel illness, which is not fully understood. Whether an individual has traveled outside their respective country or never left their community, COVID-19 is a highly contagious illness,...
展开
The coronavirus disease 2019 (COVID-19) is a novel illness, which is not fully understood. Whether an individual has traveled outside their respective country or never left their community, COVID-19 is a highly contagious illness, which can result in high death rates. Biobanks will play a role in providing tools to examine data from those receiving treatment along with reviewing the current and long treatment outcomes associated with this novel coronavirus disease. A diverse, global network made up of laboratory scientists, clinical researchers, epidemiologists, data science teams, physicians, and so on must have a standardized, collaborative, virtual biobanking solution to share clinical expertise and evidence-based solutions. This virtual biobank must be centrally managed to ensure standardized quality assurance and quality control efforts. Virtual biobanks will eliminate the need to transport samples between two locations for a specific study, minimizing the risk of contamination. It is necessary for virtual biobanks to upload imaging data from those patients diagnosed with COVID-19. Standardized, collected information will be essential in the area of discovery and validation of disease markers as well as novel therapeutic strategies. It is essential for biobanks to collect COVID-19 specimens along with corresponding clinical and demographic data from COVID-19 diagnostic testing. Because COVID-19 is an acute respiratory illness, proper collection procedures must be in place to collect respiratory samples for biobanking purposes. A preconfigured purpose-built COVID-19 Laboratory Information Management System (LIMS) is an efficient tool to seamlessly manage a data sharing network. Data entered into LIMS will be beneficial in designing much needed clinical trials to address any unmet needs to better address clinical treatment and outcomes. The partners or entities associated with the COVID-19 data sharing network will be able to effectively communicate, view data, and images associated with their respective research interest to advance COVID-19 research and data driven, clinical care.
收起
摘要 :
Background?Following a massive outbreak of the coronavirus disease 2019 (COVID-19) pandemic, a significant number of survivors are still suffering from residual symptoms and complications. We designed a preliminary study to evalua...
展开
Background?Following a massive outbreak of the coronavirus disease 2019 (COVID-19) pandemic, a significant number of survivors are still suffering from residual symptoms and complications. We designed a preliminary study to evaluate such symptom spectra in COVID-19 patients who had been discharged from the hospital. Methods?A telephone interview was conducted with 100-randomly chosen hospital-discharged COVID-19 survivors from the electronic patient record. The interview structure and method were developed by a panel of experts. A specially trained group conducted the interviews and data collection. The statistical analysis was performed in accordance with the data type (continuous and categorical). Group comparisons were also done between intensive care unit (ICU) versus general ward admission, and patients discharged between 3 and 12 weeks versus more than 12 weeks. Additionally, world clouds were used for better visualization of various prevalent symptoms. Results?Eighty-two participants were finally included for interview after preliminary screening. Fifty-three patients (64.6%) were male participants; 74.4% had at least one symptom. In general, fatigue, cough, insomnia, and shortness of breath were the most common persistent symptoms. Symptoms were more prevalent among the patients discharged from ICU compared with those discharged from the general ward. Cough, loss of appetite, depression, and incoherence were more common in patients after 12 weeks of hospital discharge. Conclusion?There is a wide range of persistent symptoms in the COVID-19 survivors who have been discharged from the hospital. Some symptoms arise or persisted even after 12 weeks. Based on the study results, available literature, and expert consensus, an assessment form has been developed that could be used for further research and clinical assessment of similar problems. Large-scale epidemiological study (longitudinal and cross-sectional) is needed to understand the nature and prevalence of the postacute phase of COVID-19 at the country level. The results of this study could inform the stakeholders and policymakers for taking necessary steps toward a further decision.
收起
摘要 :
Tduration of persistent protection after vaccination against COVID-19 is the sum of many factors, including the used formulation, the vaccination schedule, individual predisposition, clinical status and the SARS-CoV-2 variant. (Th...
展开
Tduration of persistent protection after vaccination against COVID-19 is the sum of many factors, including the used formulation, the vaccination schedule, individual predisposition, clinical status and the SARS-CoV-2 variant. (There is a tendency that?) vaccination regimens demonstrate lower levels of immunity against the currently predominant Omicron variant, which results in the need for subsequent booster doses. Thus, bivalent formulations have been recently developed to additionally target the Omicron variant. Accordingly, the purpose of this study was to assess whether bivalent vaccines would increase interest in vaccination among Poles. For this purpose, an original questionnaire distributed via the Internet and targeting Poles over the age of 18 was used. Results The survey included 594 respondents, the vast majority of whom were women (79.3%), residents of large cities (44.7%) and those with a university education (86.3%). The average age was 36.6 ± 9.67 years. Only 48.7% of respondents had heard of bivalent vaccination against COVID-19. 408 (72.3%) respondents confirmed that if they had the choice, they would opt for the bivalent preparation. People who have already taken at least 1 booster dose are by far the most common group. Among the unvaccinated, the percentage is only 8.9%. For 190 (33.7%) of respondents, the availability of bivalent preparations will help accelerate their decision to vaccinate against COVID-19. Conclusions Bivalent vaccination is an important part of the fight against the ongoing COVID-19 pandemic. However, it is forecasted that its implementation will not contribute significantly to the increase in vaccination-related interest rate among those previously unvaccinated or only after the basic regimen. Therefore further observations in this direction are necessary.
收起
摘要 :
Обоснование . В научной литературе появляется всё больше данных о различиях в ?чувствительности и восприимчивости к инфекции...
展开
Обоснование . В научной литературе появляется всё больше данных о различиях в ?чувствительности и восприимчивости к инфекции SARS-CoV-2, которые проявляются у пациентов в диапазоне от бессимптомного течения заболевания до тяжёлой дыхательной недостаточности и необходимости длительной искусственной вентиляции лёгких. Основные причины этого спектра клинических проявлений остаются неясными. Определение факторов риска, способных вызвать такую вариацию клинических симптомов, важно для выявления наиболее восприимчивых групп населения с наибольшим риском. Это должно помочь улучшить меры профилактики, сократить количество госпитализаций и снизить смертность от заболевания. Ранее для генетических маркеров rs11385942 G>GA и rs657152 A>C была показана связь с тяжестью течения COVID-19. Цель работы . Оценить вклад носительства полиморфных маркеров rs11385942 G>GA и rs657152 A>C на показатели тяжести течения COVID-19 у пациентов, получавших этиотропную терапию. Материалы и методы . В исследование было включено 240 ?пациентов, госпитализированных в ГБУЗ г. Москвы ?Городская клиническая больница № 15 им. О.М. Филатова ДЗМ? с диагнозом COVID-19, получавших этиотропную терапию фавипиравиром или ремдесивиром. У всех пациентов определялось носительство вариантов rs11385942 G>GA и rs657152 A>C. Сравнивались длительность стационарного лечения, частота перевода пациентов в отделение реанимации и интенсивной терапии (ОРИТ), частота наступления клинических исходов (выписан или смерть) между носителями аллельных вариантов изучаемых генетических маркеров. Результаты . Не было выявлено статистически значимых ассоциаций носительства различных вариантов rs11385942 G>GA и rs657152 A>C с длительностью госпитализации пациентов, частотой перевода пациентов в ОРИТ и наступлением того или иного исхода. Заключение . Носительство вариантов rs11385942 ?G>GA и rs657152 ?A>C не определяло показатели тяжести течения и вид клинических исходов у пациентов с COVID-19.
收起
摘要 :
? 2021 Elsevier LtdThis article presents a systematic overview of artificial intelligence (AI) and computer vision strategies for diagnosing the coronavirus disease of 2019 (COVID-19) using computerized tomography (CT) medical ima...
展开
? 2021 Elsevier LtdThis article presents a systematic overview of artificial intelligence (AI) and computer vision strategies for diagnosing the coronavirus disease of 2019 (COVID-19) using computerized tomography (CT) medical images. We analyzed the previous review works and found that all of them ignored classifying and categorizing COVID-19 literature based on computer vision tasks, such as classification, segmentation, and detection. Most of the COVID-19 CT diagnosis methods comprehensively use segmentation and classification tasks. Moreover, most of the review articles are diverse and cover CT as well as X-ray images. Therefore, we focused on the COVID-19 diagnostic methods based on CT images. Well-known search engines and databases such as Google, Google Scholar, Kaggle, Baidu, IEEE Xplore, Web of Science, PubMed, ScienceDirect, and Scopus were utilized to collect relevant studies. After deep analysis, we collected 114 studies and reported highly enriched information for each selected research. According to our analysis, AI and computer vision have substantial potential for rapid COVID-19 diagnosis as they could significantly assist in automating the diagnosis process. Accurate and efficient models will have real-time clinical implications, though further research is still required. Categorization of literature based on computer vision tasks could be helpful for future research; therefore, this review article will provide a good foundation for conducting such research.
收起
摘要 :
(1) Objectives: To evaluate the frequency and factors associated with the Post-COVID-19 Syndrome (PCS) in COVID-19 survivors after 3 and 6 months of hospital discharge; (2) Methods: We conducted a cohort study with patients who we...
展开
(1) Objectives: To evaluate the frequency and factors associated with the Post-COVID-19 Syndrome (PCS) in COVID-19 survivors after 3 and 6 months of hospital discharge; (2) Methods: We conducted a cohort study with patients who were hospitalized with COVID-19 in a referral public hospital in Brasília, Federal District, Brazil. After 3 and 6 months of discharge, patients answered a questionnaire about PCS symptoms. Poisson regression with robust variance was used to estimate the crude and adjusted prevalence ratios (PR and aPR) of PCS. (3) Results: The prevalence of PCS was 81% and 61% after 3 and 6 months of hospital discharge, respectively. The main symptoms after 3 months of discharge were hair loss (44%), fatigue (42%), and memory loss (39%); while after 6 months, they were memory loss (29%) and fatigue (27%). In the multivariate analysis, the main factor associated with PCS was female gender (aPR): 1.28 (1.16-1.41) and 1.60 (1.34-1.90), 3 and 6 months after hospital discharge, respectively. Hypercholesterolemia was also associated with PCS after 3 months aPR of 1.15 (1.04-1.27). After 6 months of discharge, obesity [aPR: 1.22 (1.03-1.45)] and pronation [aPR: 1.15 (1.06-1.25)] were relevant associated factors. (4) Conclusions: The prevalence of PCS was high in COVID-19 survivors who had the moderate and severe forms of the disease. Memory loss was the most persistent symptom. Our data pointed to female gender, hypercholesterolemia, obesity, and pronation during hospitalization as relevant PCS-associated risk factors.
收起
摘要 :
BACKGROUND:Monoclonal antibody (mAb) treatment for COVID-19 is associated with improved clinical outcomes. However, there is limited information regarding the impact of treatment on symptoms and the prevalence of post-COVID Condit...
展开
BACKGROUND:Monoclonal antibody (mAb) treatment for COVID-19 is associated with improved clinical outcomes. However, there is limited information regarding the impact of treatment on symptoms and the prevalence of post-COVID Conditions (PCC). Understanding of the association between time to mAb infusion and the development of PCC is also limited.METHODS:This longitudinal study was conducted among patients with COVID-19 who received mAb infusions at a Federally Qualified Health Center in San Diego, CA. A series of telephone interviews were conducted at baseline and follow-up (14?days and 28+?days). A comprehensive symptom inventory was completed and physical and mental health status were measured using PROMIS-29 and PHQ-2. Pearson's Chi-squared tests and independent two-sample t-tests were performed to test for association between time to mAb infusion and outcomes at follow-up. A Poisson regression model was used to analyze whether time to mAb infusion predicts risk of developing PCC.RESULTS:Participants (N?=?411) were 53% female, ranged in age from 16 to 92?years (mean 50), and a majority (56%) were Latino/Hispanic. Cross-sectional findings revealed a high symptom burden at baseline (70% of patients had cough, 50% had fever, and 44% had headache). The prevalence of many symptoms decreased substantially by the final follow-up survey (29% of patients had cough, 3% had fever, and 28% had headache). Longitudinal findings indicated that 10 symptoms decreased in prevalence from baseline to final follow-up, 2 remained the same, and 14 increased. The severity of symptoms and most patient-reported physical and mental health measure scores decreased over time. The prevalence of PCC was 69% when PCC was defined as?≥?1 symptom at final follow-up. Time to mAb infusion was not significantly associated with any outcome at follow-up. Time to infusion was not associated with PCC status at final follow-up in the crude or adjusted Poisson regression models.CONCLUSIONS:The prevalence of PCC was high among this patient population following COVID-19 mAb treatment. Time to mAb infusion did not predict the development of PCC. Further research in these areas is essential to answer urgent clinical questions about effective treatments of COVID-19.
收起
摘要 :
Using household survey data and reported SARS-CoV-2 cases in the United States, we estimate at least 3.0-5.0 million adults, or 1.2%-1.9% of the US adult population, had activity-limiting post-COVID conditions of >= 1 month's dura...
展开
Using household survey data and reported SARS-CoV-2 cases in the United States, we estimate at least 3.0-5.0 million adults, or 1.2%-1.9% of the US adult population, had activity-limiting post-COVID conditions of >= 1 month's duration on 1 November 2021. Background Although most adults infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) fully recover, a proportion have ongoing symptoms, or post-COVID conditions (PCC), after infection. The objective of this analysis was to estimate the number of United States (US) adults with activity-limiting PCC on 1 November 2021. Methods We modeled the prevalence of PCC using reported infections occurring from 1 February 2020 to 30 September 2021, and population-based, household survey data on new activity-limiting symptoms >= 1 month following SARS-CoV-2 infection. From these data sources, we estimated the number and proportion of US adults with activity-limiting PCC on 1 November 2021 as 95% uncertainty intervals, stratified by sex and age. Sensitivity analyses adjusted for underascertainment of infections and uncertainty about symptom duration. Results On 1 November 2021, at least 3.0-5.0 million US adults, or 1.2%-1.9% of the US adult population, were estimated to have activity-limiting PCC of >= 1 month's duration. Population prevalence was higher in females (1.4%-2.2%) than males. The estimated prevalence after adjusting for underascertainment of infections was 1.7%-3.8%. Conclusions Millions of US adults were estimated to have activity-limiting PCC. These estimates can support future efforts to address the impact of PCC on the US population.
收起
原文获取